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Pharmacological activation of a novel p53-dependent
S-phase checkpoint involving CHK-1
A Ahmed1, J Yang1,3, A Maya-Mendoza2, DA Jackson2 and M Ashcroft*,1
We have recently shown that induction of the p53 tumour suppressor protein by the small-molecule RITA (reactivation of p53
and induction of tumour cell apoptosis; 2,5-bis(5-hydroxymethyl-2-thienyl)furan) inhibits hypoxia-inducible factor-1a and
vascular endothelial growth factor expression in vivo and induces p53-dependent tumour cell apoptosis in normoxia and
hypoxia. Here, we demonstrate that RITA activates the canonical ataxia telangiectasia mutated/ataxia telangiectasia and Rad3-
related DNA damage response pathway. Interestingly, phosphorylation of checkpoint kinase (CHK)-1 induced in response to
RITA was influenced by p53 status. We found that induction of p53, phosphorylated CHK-1 and cH2AX proteins was significantly
increased in S-phase. Furthermore, we found that RITA stalled replication fork elongation, prolonged S-phase progression and
induced DNA damage in p53 positive cells. Although CHK-1 knockdown did not significantly affect p53-dependent DNA damage
or apoptosis induced by RITA, it did block the ability for DNA integrity to be maintained during the immediate response to RITA.
These data reveal the existence of a novel p53-dependent S-phase DNA maintenance checkpoint involving CHK-1.
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Solid tumours characteristically contain areas of low oxygen
tension (hypoxia). Hypoxia stabilises the expression of
the hypoxia-inducible factor (HIF)-a transcription factor.
Deregulated overexpression of HIF-a in tumour cells initiates
a transcriptional programme that renders tumour cells
resistant to chemotherapy and radiotherapy, resulting in a
more aggressive and metastatic cancer phenotype.1 Targeting
HIF/hypoxia signalling, therefore, has become an attractive
strategy for the development of new cancer treatments.2
The p53 tumour suppressor protein is a potent negative
regulator of HIF-1a, mediating both apoptotic3,4 and anti-
angiogenic effects when overexpressed.5,6 HIF-1a accumula-
tion in hypoxia is blocked by overexpression5 or activation6 of
p53, and HIF-1-dependent transcription negatively correlates
with p53 status.7 p53 is mutated in about 50% of human
cancers, and several agents have been described that can
reactivate mutant8,9 or activate wild-type p5310–12 in tumour
cells. However, many of these emerging p53-targeted agents
have not yet been evaluated for their effectiveness at
mediating tumour cell death in normoxia and hypoxia. We
have been exploring the mechanistic properties of the small-
molecule activator of p53, RITA (reactivation of p53 and
induction of tumour cell apoptosis; 2,5-bis (5-hydroxymethyl-
2-thienyl) furan, NSC-652287).12–14 RITA was originally
identified in a cell-based screen using the National Cancer
Institute compound library and was shown to mediate p53-
dependent antitumour activity in vivo.12 Subsequently, we
have found that RITA significantly inhibits HIF-1a induction
and elicits p53-dependent apoptotic responses in normoxia
and hypoxia, and promotes both apoptotic and antiangiogenic
effects in vivo.15 RITA was originally proposed to stabilise and
activate p53 by disruption of the p53–human double minute 2
(HDM2) interaction,12 and mediate p53-dependent apoptosis
and other cellular responses via the regulation of p53
transcriptional responses.16 Recently, we have shown that
RITA mediates an effect on the protein translation machinery
and downregulates both HDM2 and p21 protein levels in a
dose- and time-dependent manner while concurrently indu-
cing apoptosis.15 Moreover, and consistent with previous
reports indicating that RITA causes protein–DNA and DNA–
DNA intrastrand crosslinks,13,14 we have found that RITA
activates a DNA damage response.17 Collectively, these
studies indicate that RITA exhibits a complex mechanism of
action that leads to p53 activation and apoptotic responses.
Here, we further explore the mechanism of action of RITA,
with particular focus on the DNA damage response. We
demonstrate that RITA activates the canonical ataxia telan-
giectasia mutated/ataxia telangiectasia and Rad3-related
(ATM/ATR) DNA damage cascade and induces DNA
damage in p53 positive cells. Interestingly, RITA also
mediates checkpoint kinase (CHK)-1 phosphorylation and
slows replication fork elongation and S-phase progression in a
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p53-dependent manner. Loss of CHK-1 does not significantly
affect p53-mediated apoptotic responses induced by RITA,
but does significantly enhance DNA damage upon short term
exposure to RITA. Our study identifies a novel p53-dependent
S-phase checkpoint involving CHK-1.
Results
RITA induces a DNA damage response. Recently, we
have found that RITA can mediate significant tumour cell
apoptosis in normoxia and hypoxia in a p53-dependent
manner and activate a DNA damage response in vitro and
in vivo.15 Consistent with our previous studies,17 here, we
found that RITA induced phosphorylation of the histone
protein H2AX at Ser139 ((gH2AX); Figure 1a), which is
usually associated with DNA damage-induced stress.18
Concurrently, we found that RITA increased cleaved poly
ADP ribose polymerase (PARP; Figure 1a) and the
percentage of cells in sub-G1 (Figure 1b), indicative of
increased apoptosis. Both DNA damage and apoptotic
responses induced by RITA were observed in normoxia
and hypoxia, only in p53-positive cells (Figure 1).
To further explore the DNA damage response induced by
RITA, we first assessed the phosphorylation status of p53
in response to RITA, as phosphorylation of p53 within the
N-terminus is usually induced by genotoxic stress.19 p53þ /þ
HCT116 cells were treated with RITA over a concentration
curve and assessed for Ser15, Ser20 and Ser46 phosphor-
ylation of p53 (Figure 2a). We found that RITA induced
N-terminal phosphorylation of p53 (Figure 2a). DNA damage
is usually sensed by the PI-3K-related protein kinases ATM
and ATR, which activate the transducer checkpoint kinases
CHK-2 and CHK-1, respectively.20 ATM/ATR directly phos-
phorylates p53 at Ser15, whereas CHK-2/CHK-1 phospho-
rylates Ser20 on p53.21 Consistent with activation of the
canonical ATM/ATR DNA damage response pathway, we
found that RITA also induced phosphorylation of Ser345 on
CHK-1 and Thr68 on CHK-2 (Figure 2a), and increased
gH2AX in a dose-dependent manner (Figure 2a). These
responses correlated with a dose-dependent increase of cells
in sub-G1, indicative of apoptosis (Figure 2a, graph). In
addition, we found that induction of phosphorylated CHK-1,
CHK-2, p53 and gH2AX proteins was time-dependent
(Figures 2b and c) and correlated with a time-dependent
increase in cells in sub-G1 (Figure 2d). Thus, the DNA
damage response induced by RITA is both dose- and
time-dependent.
We found that the induction of phosphorylated p53
(Ser15 and Ser20), CHK-1 and CHK-2 proteins in response
to RITA was blocked by wortmannin, a kinase inhibitor
of ATM/ATR and other phosphatidylinositol 3-kinase
family members (Figure 2e), whereas the induction of
cleaved PARP was only marginally affected (Figures 2e
and f). Interestingly, we found that wortmannin had no
significant effect on the induction of eukaryotic initiation
factor-2a phosphorylation or the downregulation of
HDM2 and p21 proteins induced by RITA (Figure 2f),
which we have previously described.15 These data indicate
that the DNA damage and translational responses induced
by RITA are potentially separable processes. As we
would anticipate from the wortmannin effects observed
(Figures 2e and f), in response to RITA, we found that ATM
or ATR siRNA blocked the induction of phosphorylated
CHK-1 and CHK-2 (Figure 2g), which are downstream
targets of ATR and ATM, respectively. Finally, further
analysis of the DNA damage response induced by RITA
indicated a slight but measurable increase in DNA damage
in p53-positive HCT116 and MCF-7 cells (Figures 3a and b),
which was not observed in p53-null HCT116 or Saos-2
cells (Figure 3c). Taken together, these data suggest
that RITA activates the canonical ATM/ATR DNA damage
response pathway and induces DNA damage in p53
positive cells.
RITA stalls replication fork elongation and prolongs
S-phase progression in p53-positive cells. We have
previously observed that most cells treated with RITA
showed an intense pan-nuclear staining of gH2AX.17 A
similar pan-nuclear staining pattern was observed in
response to hydroxyurea treatment.17,22 This type of DNA
damage response is indicative of potential stalling of the
replication fork or inhibition of replication fork elongation, and
can be mediated during processing of bulky DNA lesions.22
During replication, cells usually respond to DNA damage by
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Figure 1 RITA induces p53-dependent apoptosis in normoxia and hypoxia.
(a and b) p53/HCT116, p53þ /þHCT116 cells or Saos-2 (p53 null) cells were
treated with or without RITA (500 nM) for 16 h in either normoxia or hypoxia (1% O2).
(a) Western blots show cleaved PARP (89 kDa), p53 and phosphorylated-S139-
gH2AX proteins. Actin was used as a loading control. (b) In parallel with the western
analysis described in a, cells were harvested for flow cytometric analysis. Cells were
fixed and stained using propidium iodide to visualise DNA profiles. The graph shows
the percentage (%) of cells in sub-G1 in response to the treatments as indicated.
Data is averaged from three independent experiments
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activating an intra-S-phase checkpoint.23 Therefore, we next
assessed whether RITA mediated a p53-dependent DNA
damage response by affecting the replication fork and
S-phase progression. To do this, we treated p53/ or
p53þ /þ HCT116 cells with RITA and performed a DNA fibre
assay, as previously described.24,25 We found that RITA
induced a marked increase in the percentage of replication
forks in p53þ /þ cells but not in p53/ cells (Figure 4a,
compare p53/ with p53þ /þ , lanes 2 and 3). Intriguingly,
this effect was only observed in a sub-population of
replicons, such that the second and third classes were very
substantially affected by RITA treatment, whereas the
seventh/eight/ninth classes were less affected (Figure 4a,
compare untreated versus RITA-treated in p53þ /þ cells,
lanes 2 and 3 with lanes 7, 8 and 9). Statistical analysis
(t-test) showed significance (P-value¼ 4.85E25) in p53þ /þ
HCT116 cells for untreated versus RITA-treated (Figure 4b).
Visualisation of DNA foci using bromodeoxyuridine (BrdU)
pulse labelling and immunohistochemical analyses was
performed to assess S-phase progression in unsynchro-
nised p53/ and p53þ /þ HCT116 cells. We found that
although the S-phase programme was maintained upon
treatment with RITA, our data indicated that S-phase was
prolonged at mid-late stages (Figure 4c).
Previous studies have shown that CHK-1 predominantly
regulates DNA replication, fork elongation and effects
S-phase progression.25 As we found that RITA induced
a p53-dependent increase in replication fork number
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Figure 2 RITA induces a DNA damage response. (a) Western blot analysis of DNA damage response markers in p53þ /þHCT116 cells treated with the indicated
concentrations of RITA for 16 h. Western blot analysis shows p53, phosphorylated p53 (S15, S20, S46), phosphorylated-S345-CHK-1, phosphorylated-T68-CHK-2,
phosphorylated-S139-gH2AX, CHK-1 and CHK-2 proteins. Actin was used as a loading control. In parallel, cells were harvested for flow cytometric analysis. Cells were fixed
and stained using propidium iodide to visualise DNA profiles. The graph shows the percentage (%) of cells in sub-G1 in response to RITA treatment as indicated. Data is
averaged from three independent experiments. (b) Western blot analysis of DNA damage response markers in p53þ /þHCT116 cells treated with RITA (1mM) for the
indicated time. Western blot analysis shows p53, phosphorylated-S345-CHK-1, phosphorylated-T68-CHK-2, phosphorylated-S139-gH2AX, CHK-1 and CHK-2 proteins Actin
was used as a loading control. (c) Western blot analysis shows p53, phosphorylated p53 (S15 and S46) and phosphorylated-S139-gH2AX in p53þ /þHCT116 cells and p53/
HCT116 cells treated with RITA (1 mM) for the indicated time. Actin was used as a loading control. (d) In parallel with the western analysis described in c, cells were harvested
for flow cytometric analysis. Cells were fixed and stained using propidium iodide to visualise DNA profiles. The graph shows the percentage (%) of cells in sub-G1 in response
to RITA treatment as indicated. Data are averaged from three independent experiments. (e and f) p53þ /þHCT116 cells were treated with RITA (1 mM) in the presence or
absence of wortmannin (10 mM) for 16 h and assessed by western blot for p53, phosphorylated p53 (S15 and S20), phosphorylated-S1981-ATM, phosphorylated-S345-CHK-
1, phosphorylated-T68-CHK-2 proteins, HDM2, p21, phosphorylated eukaryotic initiation factor-2a (eIF-2a), total eIF-2a, and cleaved PARP proteins. Actin was used as a
loading control. (g) p53þ /þHCT116 cells were transfected with a non-silencing control siRNA (NSC), ATM siRNA or ATR siRNA. Cells were treated with RITA (500 nM) for
24 h then harvested for western analysis. Western blot analysis shows p53, phosphorylated-S345-CHK-1, phosphorylated-T68-CHK-2, CHK-1 and CHK-2 proteins. Actin was
used as a loading control
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(Figures 4a and b) and affected S-phase progression
(Figure 4c), we next assessed whether CHK-1 phosphoryla-
tion was also affected by p53 status. To do this, p53/ and
p53þ /þ HCT116 cells were treated with RITA. We found that
both CHK-1 and CHK-2 were phosphorylated in response to
RITA treatment (Figure 4d). However, we found that
phosphorylation of CHK-1 at Ser345 induced by RITA was
affected by p53 status, whereas RITA-induced phosphory-
lated CHK-2 was observed in both p53/ and p53þ /þ cells to
a similar extent (Figure 4d). Taken together, our studies
indicate that RITA activates a p53-dependent DNA damage
response involving CHK-1 that functions to stall DNA
replication fork elongation and prolong S-phase progression.
RITA induces p53 and phosphorylated CHK-1 and cH2AX
proteins in S-phase. Given that RITA induces significant
p53-dependent apoptotic (Figure 1) and S-phase responses
(Figure 4), we next explored the induction of p53 and gH2AX
proteins in sub-G1 and S-phase cell populations
using fluorescence-activated cell sorting (FACS) analysis
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Figure 3 RITA induces DNA damage in p53-positive cells. (a) p53þ /þHCT116 and (b) MCF-7 cells were treated with RITA at the indicated concentrations and assessed
for DNA strand breaks using the comet assay (upper panels show representative Sybr green-stained comets (upper row) and the respective digitally converted images (lower
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(Figure 5a). We found that p53 protein was induced in
response to RITA in all cell cycle phases (G1¼ 38%,
S¼ 43% and G2¼ 40%). Interestingly, after treatment with
RITA, a higher proportion of cells in S-phase were positive for
gH2AX protein (G1¼ 22%, S¼ 26% and G2¼ 10%). More-
over, we found a dose- and time-dependent increase in
both p53 and gH2AX protein levels in cells in S-phase
in response to RITA (Figures 5b and c). In addition, we found
a significant increase in the proportion of cells in
S-phase expressing phosphorylated CHK-1 protein (Figures
5d and e), whereas an increase in cells expressing
phosphorylated CHK-1 protein was not observed in cells
in sub-G1 (data not shown). Together, these data suggest
that RITA activates a p53-dependent S-phase checkpoint
involving CHK-1.
CHK-1 knockdown does not affect RITA-induced
apoptosis but affects DNA damage in cells treated with
RITA. To further assess whether CHK-1 was required for
p53-dependent apoptotic and DNA damage responses
Alexa-488
untreated
Early Mid Late
Alexa-488RITA
p53-/- p53+/+
P-S345-CHK1
p53
PARP
116 kDa
89 kDa
P-T68-CHK2
P-S139-H2AX
-actin
(M)RITA: 0 1 0 1
p53 -/-p53 +/+
untreated untreated
RITA: 500nM RITA: 500nM
%
 o
f f
o
rk
s
%
 o
f f
o
rk
s
fork length fork length
%
 o
f f
o
rk
s
%
 o
f f
o
rk
s
fork lengthfork length
Cell line Kbp/minMean SD n
p53+/+ untreated
p53+/+
RITA: 500nM 0.9
p53-/-
untreated 0.95
p53-/-
RITA: 500nM 0.97
35 45
40
35
30
25
20
15
10
5
0
40
35
30
25
20
15
10
5
0
30
25
20
15
10
5
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
0
30
25
20
15
10
5
0
<10 <15 <20 <25 <30 <35 <40 <45 <50 <55 <60 <65 <70 <80<5
121 2 3 4 5 6 7 8 9 10 11 13 14 15
<10 <15 <20 <25 <30 <35 <40 <45 <50 <55 <60 <65 <70 <80<5
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
<10 <15 <20 <25 <30 <35 <40 <45 <50 <55 <60 <65 <70 <80<5
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
<10 <15 <20 <25 <30 <35 <40 <45 <50 <55 <60 <65 <70 <80<5
1.125 0.34 601
0.34 551
0.26 577
0.26 300
Figure 4 RITA stalls replication fork elongation and slows S-phase progression in p53-positive cells. (a) DNA fibre assay of p53/ and p53þ /þHCT116 cells treated with
RITA (500 nM) for 16 h. Graphs show percentage (%) number of forks versus fork length for each condition as indication. (b) Table (lower panel) shows a summary of the
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induced by RITA, we knocked down CHK-1 using siRNA
(Figure 5e). Interestingly, we found that CHK-1 knockdown
had no significant effect on p53-dependent apoptotic
responses induced by RITA (Figures 6a and b), whereas
the inhibition of caspase-3 activation by the inhibitor
Z-DEVD-FMK blocked the increase in cells in sub-G1
(Figure 6a) and the increase in cleaved PARP (Figure 6b),
but had no significant effect on phosphorylated CHK-1
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induced by RITA (Figure 6c). CHK-1 has an important role in
DNA repair26 and is essential for the maintenance of
genomic stability,27 particularly during DNA replication
and replication fork progression.25,28–30 Thus, we next
investigated whether CHK-1 knockdown affected the DNA
damage response induced by RITA. We found that CHK-1
knockdown had no significant effect on the small amount of
accumulated DNA damage at 24 h of exposure to RITA
(Figure 6d), nor was there any significant effect on the gH2AX
induced by RITA in CHK-1 knockdown cells at this time point
(Figure 6e). Notably, a previous report has shown that
phosphorylation at Ser345 on CHK-1 increases its turnover,
and thereby reduces total CHK-1 protein levels.31
Consistently, we found that total CHK-1 protein levels
decreased in the presence of RITA (Figure 6e). This effect
was more dramatic in the presence of CHK-1 siRNA (Figure 6e).
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Figure 6 CHK-1 knockdown does not affect RITA-induced apoptosis but significantly enhances DNA damage in cells treated with RITA. (a and b) p53þ /þHCT116 cells
transiently transfected with a non-silencing control (NSC) siRNA duplex and siRNA to CHK-1 and treated with RITA (1 mM) for 16 h in the presence and absence of the
caspase-3 inhibitor Z-DEVD-FMK. Cells were harvested for flow cytometric analysis (a) or western analysis (b). (a) Graph shows the percentage of cells within sub-G1, as
indicated. Data are representative of two independent experiments (±S.D.). (b) Western blot analysis shows p53 and CHK-1 proteins. Actin was used as a loading control.
(c) p53þ /þHCT116 cells treated with RITA (1mM) for 16 h in the presence and absence of the caspase-3 inhibitor Z-DEVD-FMK. Western blot analysis shows PARP, p53,
CHK-1 and phosphorylated-S139-gH2AX proteins. Actin was used as a loading control. (d) p53þ /þHCT116 cells transiently transfected with a NSC siRNA duplex and siRNA
to CHK-1 and treated with RITA (500 nM) for 16 h and harvested for assessment of DNA damage using the Comet Score software (TriTek Corporation, Sumerduck, VA, USA).
Graph shows mean olive moment (B100 comets/sample) for each condition as indicated. As a positive control for DNA damage, cells were treated with H2O2 (100mM for
20 min). (e) In parallel with d, cells were harvested for western blot analysis. Western blots show p53, CHK-1 and phosphorylated-S139-gH2AX proteins. Actin was used as a
loading control. (f) p53þ /þHCT116 cells transiently transfected with a NSC siRNA duplex, CHK-1 and/or CHK-2 siRNA and treated with RITA (500 nM) for 1 h. The untreated
control samples were harvested at 0 h. Cells were harvested for assessment of DNA damage using a comet assay, as described in d. Graph shows mean olive moment
(B100 comets/sample) for each condition as indicated
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Finally, consistent with a role for CHK-1 in DNA repair
and maintenance,26,27 we found that CHK-1 but not CHK-2
knockdown significantly enhanced DNA damage induced
at only 1 h of RITA treatment (Figure 6f), indicating that CHK-1
is essential for maintaining DNA integrity upon short term
exposure of cells to RITA. Consistently, we found that CHK-1
phosphorylation was induced by RITA during this time frame
(data not shown).
Discussion
HIF is upregulated in most human cancers due to changes in
tumour microenvironmental stimuli and genetic abnormal-
ities.1 Of particular interest, is the small-molecule approaches
that have been taken recently to target the HIF pathway as a
basis for the development of new therapeutics in the treatment
of cancer.2,32 The p53 tumour suppressor protein is a potent
negative regulator of HIF signalling in tumours.5 We have
recently shown that small-molecule activator of p53, RITA,
can mediate both antiangiogenic effects via blockade of the
HIF pathway and elicit apoptosis in hypoxic tumour cells
in vitro and in vivo.15 Intriguingly, unlike other p53-activating
agents, RITA causes significant tumour cell apoptosis in
normoxia and hypoxia (1% O2), without eliciting either a
measurable G1 and/or G2 arrest.15 Given that hypoxic
tumour cells expressing high basal levels of HIF-a are usually
resistant to killing by conventional radio and chemotherapeutic
agents, in this study, we further investigated the mechanistic
properties of RITA, with particular focus on exploring the DNA
damage response.
Here, we found that RITA activated the canonical ATM/ATR
DNA damage response pathway that leads to activation
of CHK-1 and CHK-2 phosphorylation. Intriguingly, however,
and confirming our recent findings,17 we found that the
induction of phosphorylated CHK-1 and gH2AX proteins
observed in response to RITA was dependent on p53 status.
Previous studies have reported a p53-dependent DNA
damage checkpoint.33,34 Activation of a p53-dependent
S-phase DNA damage checkpoint occurs to delay DNA
synthesis and to allow time to resolve a potential replication
block.33,35 Our earlier immunohistochemical analyses
showed that RITA induced a pan-nuclear localisation of
gH2AX opposed to localisation to discrete nuclear foci.17 This
type of DNA damage response indicates potential stalling of
the replication fork or is mediated during processing of bulky
DNA lesions.22 Indeed, we found that RITA induced a p53-
dependent increase in replication fork number in a sub-
population of replicons. Notably, a decline in replication fork
rate is known to be consistent with increased rates of local
origin activation and higher replication fork densities,25
indicating that RITA stalled DNA replication elongation and
affected replication fork rate.
Consistent with these observations, we found that treat-
ment of cells with RITA also prolonged mid-late S-phase
progression in p53-positive cells. Our findings indicate
that RITA activates a p53-dependent checkpoint that may
involve CHK-1.
CHK-1 has been shown to have an important role in
regulating DNA replication fork elongation and S-phase
progression.25 In response to RITA, we found that the relative
percentage of cells in S-phase expressing either p53 or
gH2AX protein was increased compared with other cell cycle
phases. Concurrently, we observed a significantly high
percentage of cells in S-phase expressing phosphorylated
CHK-1 upon RITA treatment. Activation of CHK-1 is crucial for
eliciting replication checkpoints in response to DNA-dama-
ging agents, providing protection to cells by allowing a slowing
of S-phase progression,28,29 and appears to be critically
involved in stabilising stalled replication forks.30 In addition,
CHK-1 is important in DNA repair upon exposure to hydro-
xyurea.26,36 Interestingly, we found that knockdown of CHK-1
by siRNA had only a minimal effect on the induction of
p53-dependent apoptosis and gH2AX in response to RITA.
However, knockdown of CHK-1 but not CHK-2 significantly
increased DNA damage induced within only 1 h of RITA
treatment, indicating that the activation of CHK-1 mediated by
RITA is important for maintaining DNA integrity.
RITA was originally identified using a cell-based screen12
and proposed to bind to the N terminus of p53 and induce p53
stabilisation by disruption of the p53–HDM2 interaction.12
Other studies have shown that RITA can also cause protein–
DNA and DNA–DNA intrastrand crosslinks,13,14 thereby
suggesting that RITA may also act to stabilise p53 by
interchelating with DNA. This latter possibility is supported
by the observations that RITA activates the canonical DNA
damage response. Of significance here is our observation that
induction of CHK-1 phosphorylation by RITA is affected by
p53 status. These findings suggest that RITA functions
mechanistically both at the level of DNA and at the level of
p53. Along with its role in G1/S- and G1/M-dependent cell
cycle checkpoints, p53 has also been implicated in S-phase
processes and DNA repair. Specifically, p53 is transported to
sites of stalled DNA replication forks and binds to RAD51,37
thus p53 provides an S-phase-specific role that is indepen-
dent of its known transcriptional activities.37 In addition,
CHK-1 binds to and phosphorylates RAD51, providing a vital
role in DNA repair upon exposure to hydroxyurea.36 Collec-
tively, these events ensure that DNA integrity is maintained,
and it may be that p53 itself provides an important role in a
molecular sensor mechanism at the level of DNA.
In conclusion, our study highlights a novel role for p53 in the
activation of a p53-dependent S-phase replication checkpoint
that involves CHK-1 and functions to protect the integrity of
DNA. As we have previously shown that exposure of tumour
cells to RITA leads to significant p53-dependent apoptosis in
normoxia and hypoxia,15 it will be of particular interest to
further examine the precise molecular mechanisms under-
lying this p53-dependent S-phase checkpoint in hypoxia.
Materials and Methods
Cell culture. All tumour cell lines were maintained in Dulbecco modified Eagle’s
medium. Medium was supplemented with 10% fetal calf serum purchased from
Harlan (Oxford, UK), 100 IU/ml penicillin, 100mg/ml streptomycin and
2 mM glutamine (all purchased from Gibco/Life Technologies, Paisley, UK).
The matched colorectal cell lines p53/HCT116 and p53þ /þHCT116 have been
described previously.38 Human MCF-7 (breast carcinoma) and Saos-2
(osteosarcoma) cells were purchased from American Type Culture Collection
(Manassass, VA, USA).
siRNA duplexes and transient transfection. The siRNA to CHK-1
(50-GGTGCCTATGGAGAAGTT-30) or CHK-2 (50-CTTGAAGAGGTATCCGUGG-30)
was obtained as a gel-purified annealed duplex from Dharmacon (Lafayette, CO,
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USA) and used at a final concentration of 25 nM, respectively. The non-silencing
control siRNA duplex (50-AATTCTCCGAACGTGTCACGT-30) was obtained from
QIAGEN (Crawley, UK) and has been used by us previously.39 Transient
transfections with siRNA duplexes were carried out using HiPerfect transfection
reagent (QIAGEN) according to the manufacturer’s instructions.
Antibodies. The HIF-a monoclonal antibody was purchased from BD
Transduction Laboratories (Oxford, UK). The p53 monoclonal antibody (DO-1)
was purchased from Calbiochem (Merck Biosciences, Nottingham, UK). The CHK1
monoclonal and CHK2 polyclonal antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). The p53 polyclonal antibody, polyclonal
anti-phospho-S345-CHK1, polyclonal anti-phospho-T68-CHK2, monoclonal anti-
phospho-S15-p53, polyclonal anti-phospho-S20-p53 and polyclonal anti-phospho-
S46P-p53 were all purchased from Cell Signaling Technologies (Danvers, MA,
USA). The anti-phospho-S139-gH2AX monoclonal antibody was purchased from
Upstate (Millipore, Newtownabbey, Northern Ireland).
Inductions and drug treatments. Physiological hypoxia was achieved by
incubating cells in 1% oxygen, 5% carbon dioxide and 94% nitrogen in a LEEC
(Nottingham, UK) dual gas incubator (GA-156). The hypoxic mimetic agent,
deferoxamine mesylate (DFX), was used at a final concentration of 500mM. RITA
was obtained from the National Cancer Centre, Drug Therapeutic Program,
Frederick, MD, USA (NSC-652287) and dissolved in dimethyl sulfoxide.
Wortmannin (Sigma, Gillingham, UK) was used at a final concentration of 10 mM.
The caspase-3 inhibitor Z-DEVD-FMK (Calbiochem) was used at 50mM.
Western blot analysis. After treatment, cells were washed in ice-cold
phosphate-buffered saline and lysed in 2 sample buffer (125 mM Tris (pH 6.8),
4% SDS, 0.01% bromophenol blue, 10% b-mercaptoethanol, 10% glycerol).
Alternatively, cells were harvested in NP-40 lysis buffer (100 mM Tris (pH 8.0),
100 mM NaCl2, 1% NP-40) containing an EDTA-free protease inhibitor cocktail
(Boehringer Mannheim-Roche Diagnostics Ltd, Burgess Hill, UK) to determine
total protein concentration using a standard protein assay (Biorad, Hemel
Hempstead, UK).
Flow cytometric analysis. Cell death was analysed by FACS using a
Beckman Coulter Diagnostics machine (High Wycombe, UK). Briefly, total
populations of cells, including floating and adherent cells, were fixed in 70%
ethanol and stained with propidium iodide (50 mg/ml). Ribonuclease was added at
100mg/ml. The percentage of cells with sub-G1 DNA content was taken as a
measurement of apoptosis.
Comet assay. The comet assay was performed using reagents from Trevigen
(Gaithersburg, MD, USA) and according to the manufacturer’s instructions. Cells
were dosed for 24 h with RITA (at the concentrations indicated) in complete media.
Following dosing, cells were harvested, mixed with low-melting agarose at 2 105
cells/ml (B1000 cells/slide) and spread onto preprepared comet slides. Cells were
lysed and incubated in alkaline buffer to select for single-strand DNA breaks. Slides
were then electrophoresed using alkaline electrophoresis buffer at 4 1C, 18 v and
300 mA for 40 min. Following electrophoresis, slides were fixed, dried and stained
using Sybr green (Trevigen). Comets were viewed using a Zeiss (Zeiss Ltd, Welwyn
Garden City, Hertfordshire, UK) fluorescent microscope at  20 magnification, and
images were captured over 20 fields of view for each slide using ImagePro software
(Media Cybernetics Inc., Bethesda, MD, USA). The relative length and intensity of
Sybr green-stained nuclei (comets) were proportional to DNA damage in individual
nuclei. This was quantified using an algorithm for Olive tail moment on the
CometScore software (TriTek Corporation, Sumerduck, VA, USA). At least 100
comets were analysed for each treatment. A 20-min dose of 100mM hydrogen
peroxide at 4 1C was used as a positive control for DNA damage.
DNAfibre assay. Replication tracks were labelled in culture medium containing
25mM BrdU. RITA (500 nM) was added 16 h before each experiment. DNA fibre
spreads were prepared, as previously described.24 BrdU-labelled tracks were
detected with BrdU anti-sheep antibody (Biodesign, Lewisville, TX, USA; M20105S;
1:1000 dilution; 1 h at 20 1C) using either Cy3- or AlexaFluor-488-conjugated
donkey anti-sheep secondary antibody (Invitrogen Ltd, Paisley, UK). Fibres were
examined using a Zeiss LSM 510 confocal microscope using a  100 (1.4NA) lens,
labelled tracks measured using the LSM software (Zeiss Ltd) (white bars on
individual images show examples of measurements recorded) and converted to kbp
using a conversion factor of 1 mm¼ 2.59 kbp. Measurements were recorded in
randomly selected fields (selected at low power) from dispersed, untangled areas of
the DNA spread. As the analysis of single, unbroken fibres is a key, routine quality
control for spreading of different cell types under different experimental conditions
was performed using direct DNA labelling with YOYO.23 For the S-phase analysis,
cells were grown on microscope coverslips and pulsed labelled for 20 min with
25mM BrdU. RITA (500 nM) was added 16 h before each experiment. The cells
were fixed using 4% PF, and BrdU detected as described above and previously.25
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